Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy

Jaume Capdevila¹, Enrique Grande², Rocío García-Carbonero³, Marc Simó⁴, Mª Isabel del Olmo-García⁵, Paula Jiménez-Fonseca⁶, Alberto Carmona-Bayonas⁷, and Virginia Pubul⁸

¹Department of Medical Oncology, Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), 10B-Quiron-Teknon Barcelona, Barcelona, Spain
²Department of Medical Oncology, MD Anderson Cancer Center, Madrid, Spain
³Department of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain
⁴Department of Nuclear Medicine and Molecular Imaging, Hospital Universitari Vall d’Hebron, Barcelona, Spain
⁵Department of Endocrinology, Hospital Universitario y Politécnico la Fe de Valencia, Valencia, Spain
⁶Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, Madrid, Spain
⁷Department of Hematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, IMIB, CP13/00126, P117/0050 (ISCIII & FEDER) and Fundación Séneca (04515/GERM/06), Murcia, Spain
⁸Department of Nuclear Medicine Department and Molecular Imaging Research Group, University Hospital and Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain

Corresponding author: Jaume Capdevila, Department of Medical Oncology, Vall Hebron University Hospital, Passeig de la Vall d’Hebron, 119, 08035 Barcelona, Spain. Tel: +34 934 89 30 00; Email: jcapdevila@vhio.net

Abstract
Background: The aim of this study was to provide a guidance for the management of neuroendocrine tumors (NETs) in clinical practice.

Material and Methods: Nominal group and Delphi techniques were used. A steering committee of 8 experts reviewed the current management of NETs, identified controversies and gaps, critically analyzed the available evidence, and formulated several guiding statements for clinicians. Subsequently, a panel of 26 experts was selected to test agreement with the statements through 2 Delphi rounds. Items were scored on a 4-point Likert scale from 1 = totally agree to 4 = totally disagree. The agreement was considered if ≥75% of answers pertained to Categories 1 and 2 (consensus with the agreement) or Categories 3 and 4 (consensus with the disagreement).

Results: Overall, 132 statements were proposed, which incorporated the following areas: (1) overarching principles; (2) progression and treatment response criteria; (3) advanced gastro-enteric NETs; (4) advanced pancreatic NETs; (5) advanced NETs in other locations; (6) retreatment with radioligand therapy (RLT); (7) neoadjuvant therapy. After 2 Delphi rounds, only 4 statements lacked a clear consensus. RLT was not only recommended in the sequencing of different NETs but also as neoadjuvant treatment, while several indications for retreatment with RLT were also established.

Conclusion: This document sought to pull together the experts’ attitudes when dealing with different clinical scenarios of patients suffering from NETs, with RLT having a specific role where evidence-based data are limited.

Key words: neuroendocrine tumors; advanced; peptide receptor radionuclide therapy; progression; sequencing; neoadjuvant therapy; retreatment.

Implications for Practice
During the past years, significant advances in NETs’ molecular biology, diagnostic techniques, and therapeutic options/strategies have emerged, especially for patients with advanced or metastatic disease. The experts agree that clinical symptoms, biological markers, morphological/radiological imaging, or functional/nuclear medicine imaging alone, do not determine disease progression or treatment response. Regarding NET treatment, RLT has a relevant role in the treatment of different types of NETs, as well as neoadjuvant therapy, in the retreatment, and even to achieve resectability in certain patients with metastases.
**Introduction**

Neuroendocrine tumors (NETs) are a heterogeneous and complex group of neoplasms that arise from neuroendocrine cells and mainly affect gastro-entero-pancreatic (GEP) tissues, as well as other locations such as the lung or thymus. Over the last decades, the incidence of NETs has increased up to around 3.65 per 100 000 individuals per year, and they particularly affect the elderly. These tumors are generally diagnosed within the fifth decade of life, with men being affected slightly more often than women; around 5% of these growths are associated with hereditary predisposition syndromes. There is a wide spectrum of disease, ranging from slow-growing, indolent, and incidentally detected tumors to highly aggressive malignancies with poor prognosis. However, at diagnosis, around 40%-50% of patients living with NET already present with distant metastases. More specifically, at diagnosis, approximately 65%-95% of GEP NETs (excluding appendiceal, gastric, and rectal NETs) are already associated with hepatic metastases. This is paramount, as hepatic metastases represent the most critical prognostic factor.

During the past several years, significant advances in NETs molecular biology, diagnostic techniques, and therapeutic options/strategies have emerged, for the most part, concerning patients with advanced or metastatic NETs, resulting in earlier diagnosis while improving both prognosis and quality of life. Currently, the 5-year survival rate is estimated at up to 80%-85% in patients with well-differentiated NETs and up to 13%-54% in patients with NETs and hepatic metastases.

Surgery remains the only potentially curative therapeutic strategy in patients with NETs. On the other hand, medical treatment for these patients consists of long-acting somatostatin analogs (SSA) including octreotide and lanreotide, chemotherapy, targeted therapies like everolimus and sunitinib, loco-regional therapies, as well as radioligand therapy (RLT). The proper therapy selection depends on different factors, with some of them related to the patient (age, global health, etc.), and others to the tumor including its proliferative activity, somatostatin receptor (SSTR) expression, tumor growth rate, or disease extension.

Consensus/position documents and clinical guidelines on NETs management seek to analyze the best available evidence to provide some guidance for treatment decision-making, especially concerning sequencing therapies in situations where evidence is insufficient or even totally absent. These documents usually cover the most relevant patient and tumor phenotypes. However, in daily practice, there are often complex “borderline” scenarios or clinical situations that are not specifically covered by these documents. Consequently, physicians may face different types of patients with NET in their daily practice that prove to be really challenging.

Therefore, this consensus document sought to provide a guide for managing patients with NET, while focusing on those areas that likely generate clinical questions or controversies, such as the attitude to adopt in patients living with advanced diseases, with RLT’s role being specially highlighted.

**Material and Methods**

**Study Design**

A qualitative study was performed. Nominal group and Delphi techniques were applied to elaborate the consensus, with a comprehensive narrative review supporting the statements. An external expert in Delphi methodology guaranteed the quality of the overall process. This study was conducted in accordance with Good Clinical Practice and the current version of the revised Declaration of Helsinki (World Medical Association Declaration of Helsinki).

**Expert Panel Selection and Clinical Statement Generation**

In a first step, a multidisciplinary steering committee of 8 experts on NETs was established. They were responsible for: (1) selection of the expert panel; (2) identification of current relevant clinical questions/controversies in the management of advanced NETs; (3) generation of clinical statements to answer these questions/controversies based on their experience and an extensive and critical narrative literature review. These statements were organized in 7 main sections including: (a) overarching principles; (b) progression and treatment response criteria; (c) advanced GEP NETs; (d) advanced pancreatic NETs; (e) advanced NETs in other locations; (f) re-treatment using RLT; (g) neoadjuvant therapy; (4) definition of the consensus levels and agreement on methodology; (5) interpretation of the results from the Delphi rounds; (6) final edition of the consensus document. The steering committee did not participate in the Delphi rounds.

The expert panel comprised 26 experts that were selected according to the following criteria: (1) medical oncologist; (2) specialized in NETs with proven clinical experience of ≥8 years or ≥5 publications; (3) member of the Spanish Society of Medical Oncology (SEOM) or Spanish Task Force for Neuroendocrine and Endocrine Tumors (GETNE). In the selection process, a balanced territorial representation of Spain was considered.

**Delphi Process**

The expert panel completed 2 Delphi rounds through an online platform. After each round, a facilitator provided an anonymous summary of the experts’ forecasts from the previous round, as well as the reasons they put forth for their judgments. In the first round, the panelists voted using a 4-point Likert scale from 1 = totally agree to 4 = totally disagree. The agreement was considered if ≥ 75% of answers pertained to Categories 1 and 2 (consensus with agreement) or Categories 3 and 4 (consensus with disagreement). All statements reaching consensus in the first round did not undergo the second Delphi round. The remaining statements were analyzed by the steering committee to discern whether the lack of consensus was due to the ambiguity of the statement itself, in which case it was reformulated, or due to the issue being controversial itself, in which case the statement remained unchanged for the second Delphi round. In the second Delphi round, the statements were voted using the same categories as described for the first round. At this stage, the same criteria were established as in the first round for “consensus” in agreement and disagreement. When the response rates in Categories 1 and 2 or Categories 3 and 4 were 60%-70%, it was considered “majority”; and when it was <60%, it was called “dissent”. Finally, if this rate reached 100%, it was considered “unanimous”.

**Edition of the Document**

The steering committee wrote the position statement document. A comprehensive literature search in MEDLINE was performed to support the statements.
Results

Delphi Results

Overall, 132 statements were generated (Supplementary Tables S1-S7 depict Delphi results). In the first Delphi round, 6 statements reached the required level of agreement and did thus not pass to the second round, while 10 were reformulated. After the second round, the agreement level with the 132 statements was as follows: unanimous 26 (5 with agreement; 21 with disagreement), 78 consensus (41 with agreement; 37 with disagreement), 24 majorities (9 with agreement; 15 with disagreement), and 4 dissents. Another statement of the RLT retreatment section was finally rejected, as it was probably misunderstood (Statement 66 of the supplementary material).

Overarching Principles

There has been a broad consensus among experts (>80%) to consider that: (1) Patients with a recent NETs diagnosis should be discussed within a multidisciplinary NETs committee; (2) Implementation of improved nuclear medicine diagnostic techniques (especially 68Ga-PET-CT) has a relevant impact on treatment decision-making in patients living with NET; (3) 177Lu-DOTATATE has restructured treatment schemes for patients with gastrointestinal and pancreatic NET (Supplementary Table S1).

Progression and Response to Treatment Criteria

Disease progression and treatment response evaluation are key areas in advanced NET monitoring. However, in recent years, different factors have led to reformulating/defining disease progression and treatment response criteria, including NET heterogeneity, knowledge advances, improved imaging techniques, or new treatments and strategies.23-25

The experts agree (Supplementary Table S2) clinical symptoms, biological markers like chromogranin A (CgA), morphological/radiological imaging like RECIST v 1.1, or functional/nuclear medicine imaging do not determine disease progression or treatment response. All these display several limitations that must be considered.

A recurrence or worsening of functional symptoms due to hormone production or new symptom occurrences may suggest disease progression. However, their prior absence, as well as their reproducibility, is uncertain.26,27 In recent years, there has been an increased interest in quality of life as a surrogate marker of disease progression, but the respective results are still preliminary.28

CgA displays low sensitivity, with high within- and between-subject variations, thus causing many false positives.29,30 On the other hand, after excluding conditions with elevated gastrin levels, CgA levels have been shown to correlate with tumor burden. Moreover, recent clinical trials have demonstrated its prognostic value.31-34

A significant increase in the standardized uptake value (SUV) in positron emission tomography (PET) was not considered sufficient to ascertain disease progression. Progression is not only determined by an increase in tumor activity but also by the development of new lesions.24,35

Concerning RECIST v 1.1, although these criteria are still widely used for establishing disease progression and treatment response, their usefulness has been questioned for different reasons. Several studies have shown that tumor response to targeted therapies is rarely associated with shrinkage, as opposed to prolonged progression-free survival (PFS). Thus, other criteria like those of CHOI may be more useful for patients on targeted therapies.26,36-39 Furthermore, discrepancies have been observed between longer PFS values and low RECIST-assessed response rates (<10%),40 in addition to difficulties in assessing liver metastases, given that RECIST thresholds are not suited for the slow evolution of many NETs, which may thus be misclassified as SD.24,41

There was dissent about the consideration that CHOI criteria only apply to patients on anti-angiogenic targeted therapies.36 Preliminary data from patients with advanced NET suggest that CHOI criteria could help identify patients who might already benefit from targeted therapy at an earlier time point.37,38 Therefore, although there is not yet any robust evidence on this issue, CHOI criteria could potentially be used to assess the response to other treatment types.

Sequencing of Treatments in Gastrointestinal NETs

In this section, we discuss uncertainties that usually arise in clinical practice upon selecting the most appropriate treatment and sequencing of therapies in patients with gastrointestinal NET, especially when different therapeutic options are possible, yet without any head-to-head clinical comparative trials available (see Table 1).

First, in patients with G1-G2 small intestine NET, the panel agrees (89% consensus) that both the efficacy and safety of RLT are superior to those displayed by everolimus, whereas this is not the case in G1-G2 NETs of other intestinal locations. The NETTER-1, a phase III randomized controlled trial (RCT) involving 229 patients with advanced small bowel NETs, revealed an estimated 20-month PFS with 177Lu-DOTATATE of 65.2% versus 10.8% with octreotide, with a response rate of 18% versus 3% (P < .001), respectively, along with an acceptable safety profile.42,43 Data of colorectal NETs treated with 177Lu-DOTATE are currently scarce. Several studies have analyzed the everolimus

Table 1. Treatments for patients with advanced gastrointestinal neuroendocrine tumors.

| Tumor characteristics                      | Most appropriated treatment          |
|---------------------------------------------|-------------------------------------|
| Advanced small intestinal NETs              | G2 Peritoneal carcinomatosis         |
|                                             | Progression to SSAs - RLT            |
| Advanced gastrointestinal NETs               | G2 Multiple bone metastases          |
|                                             | Progression to SSAs - RLT            |
| Advanced gastrointestinal NETs               | G1-G2 Functional with uncontrolled hormonal symptoms and hepatic metastases |
|                                             | Progression to SSAs - RLT            |
|                                             | - RLT                               |
|                                             | - Loco-regional therapy              |

Abbreviations: NETs, neuroendocrine tumors; G, grade; SSAs, somatostatin analogs; RLT, radioligand therapy.
activity in different NET subtypes. However, the number of included patients with small bowel NETs was inferior to that of patients included with other NET subtypes. In the RADIANT-2 phase III RCT, the patient subgroup with advanced small bowel NETs displayed a median PFS of 18.6 months with everolimus plus octreotide long-acting release (LAR) versus 14 months with octreotide LAR alone. In another RADIANT-2 subanalysis, patients with advanced colorectal NETs displayed a median PFS of 29.9 months with everolimus plus octreotide LAR versus 6.6 months with octreotide LAR alone. Finally, in the RADIANT-4 phase III RCT, a placebo-controlled trial, PFS was superior with everolimus in small bowel NETs (hazard ratio [HR] = 0.71; 95% CI, 0.40-1.26) and in NETs of other locations (HR = 0.27; 95% CI, 0.15-0.51). 45

In patients with small intestine G2 NETs, peritoneal carcinomatosis-only metastases, and in those displaying progression under SSA, majority of the Delphi participants (74%) considered RLT the most appropriate option as compared to others, such as everolimus or temozolomide plus capecitabine (TEMCAP). Chemotherapy has proven very effective in these cases. Despite the lack of robust data regarding everolimus or RLT, the NETTER-1 study included some patients suffering from small bowel NETs with peritoneal carcinomatosis. 42

There was consensus (85%) in using RLT as the most suitable therapy in gastrointestinal G2 NETs with multiple bone metastases and in progression under SSAs, in comparison with other options like everolimus or TEMCAP. Chemotherapy in NETs with a high bone tumor burden may cause significant hematological toxicity. On the other hand, as data are not available for everolimus, clinical guidelines consider RLT a valid and promising option, although the available data are still preliminary.

Among therapeutic options for patients living with G1-G2 functional gastrointestinal NET with liver metastases, who are progressing under SSA with uncontrolled hormonal symptoms, RLT (96% consensus) and loco-regional treatments (majority, 73%) were considered the most appropriate modalities. A subanalysis of the NETTER-1 study demonstrated a statistical and clinically significant increase in PFS with \(^{177}\)Lu-DOTATATE in patients exhibiting low/moderate/high liver tumor burden. 46 Within the \(^{177}\)Lu-DOTATATE arm, no significant difference in PFS was observed between patients with low, moderate, or high baseline tumor burden \((P = .722)\). However, in the high-dose octreotide arm, a significant correlation was found between liver tumor burden and PFS, with median PFS of 9.1, 8.7, and 5.4 months for patients with low, moderate, and high burdens, respectively \((P = .0169)\). 48 Loco-regional treatments in small observational studies have achieved 5-year overall survival (OS) rates of 50%-80% in gastrointestinal NETs. 49,50 Notably, these treatments are also recommended by most international clinical guidelines. 31,39

Concerning nonfunctional gastrointestinal NETs progressing under long-acting SSAs, when RLT is prescribed, the Delphi participants agreed (consensus, 81%) to discontinue long-acting SSAs 4 weeks before RLT, and restart SSAs approximately 24 hours after each RLT infusion, and to use them monthly after RLT treatment completion upon progression. 32 Indeed, somatostatin and its analogs bind competitively to SSTRs and may interfere with RLT efficacy. As stated in the summary of product characteristics (SPC), administration of long-acting SSA should be avoided within 30 days of RLT. However, in functional gastrointestinal NETs progressing under long-acting SSAs with uncontrolled symptoms, if RLT is prescribed, the most accepted option (85%) was to stop long-acting SSAs and initiate short-acting octreotide 48 hours before RLT, in alignment with the product’s SPC.

Most of Delphi participants (88%) disagreed with the following statement: The short/long-term RLT toxicity proves to be lower if it is given to patients that are in progression under SSAs compared to other treatments like everolimus. There was no robust and direct evidence in this regard; although cumulative toxicity must be considered, RLT has demonstrated an acceptable safety profile regardless of prior therapy. 30,32

Sequencing of Treatments in Pancreatic NETs
We now describe the main statements for pancreatic NETs (see Table 2).

As stated in international clinical guidelines 11,15,18 and supported by the evidence from the CLARINET study, 53 there has been agreement in recommending (consensus 81%) systemic treatment with SSAs as a single-agent in patients with advanced G1-G2 pancreatic NETs, unless there is a contraindication for this.

Considering patients with advanced pancreatic NETs, the experts identified several clinical and imaging factors that may help to select a particular therapy.

In patients with asymptomatic advanced G1 pancreatic NET, SSTR expression, low tumor burden, and documented radiological progression -after over 3 years of SSAs, second-line treatment with targeted therapy (everolimus and sunitinib) would be the preferred option (consensus, 88%). The RADIANT-3 Phase III RCT, which was specifically conducted in advanced pancreatic NET patients, reported a median PFS of 11 months with everolimus versus 4.6 with placebo \((P < .001)\), along with an estimated rate of patients that were alive and progression-free at 18 months of 95% versus 34%, respectively. Most undesirable effects reported with everolimus were of G1 or G2. 34 The sunitinib efficacy was evaluated in another phase III RCT in advanced pancreatic NETs, and in this RCT, the median PFS was 29 months with sunitinib versus 10 months with placebo \((P = .002)\) in patients with high baseline tumor burden. 54

### Table 2. Treatments for patients with advanced pancreatic neuroendocrine tumors.

| Tumor characteristics | Most appropriate treatment |
|-----------------------|-----------------------------|
| Advanced G1 pancreatic NETs | **SSTR scintigraphy +** Radiologic progression under SSAs >3 years | Asymptomatic and low tumor burden - Targeted therapy |
| | Radiographic progression under SSAs <3 years | Functional - RLT |
| Advanced G2 pancreatic NETs | Non-functional, symptomatic and high tumor burden - Chemotherapy (before RLT) |

Abbreviations: NETs, neuroendocrine tumors; G, grade; SSAs, somatostatin analogs; RLT, radioligand therapy; SSTR, somatostatin receptor.
pancreatic NET patients.\(^{40}\) The median PFS was 11.4 months with sunitinib versus 5.5 with placebo (\(P < .001\)), and the objective response rate was 9.3\% versus 0\%, respectively.\(^{40}\)

In patients with advanced G1 functional pancreatic NET, SSTR expression and documented radiological progression after less than 3 years of SSAs, second-line RLT would be the preferred option for most of the Delphi participants (consensus, 92\%). Despite the lack of data from specific Phase III RCTs, there is positive evidence arising from observational studies and Phase I/II trials, whereas the RLT efficacy in functional NETs is already known.\(^{43}\) Moreover, recent systematic literature reviews and meta-analyses have demonstrated both RLT’s efficacy and safety in advanced pancreatic NET patients.\(^{55,56}\)

Considering patients with advanced insulinoma progressing under SSAs or with uncontrolled symptoms, there was a consensus (81\%) that everolimus would be preferred over RLT. Data from observational studies have shown that everolimus is an effective treatment for patients with metastatic insulinoma and refractory hypoglycemia.\(^{57-59}\) In addition, inhibition of the mTOR pathway was shown to decrease insulin secretion in patients suffering from insulinomas.\(^{57-59}\) Preliminary published data suggest that RLT can prove successful in further controlling severe hypoglycemia in malignant insulinomas.\(^{60}\)

We found that 62\% of Delphi participants recommend using at least one SSA, targeted therapy, or chemotherapy (streptozocin-based or temozolomide-based chemotherapy) before considering RLT in G1-G2 pancreatic NETs with SSTR expression. Currently, there is no evidence as to the best treatment sequencing.

In this section, consensus (96\%) was reached on considering chemotherapy (streptozocin-based or temozolomide-based chemotherapy) prior to RLT in advanced, nonfunctional G2 pancreatic NET patients suffering from symptoms due to high tumor burden. Available evidence from clinical trials\(^{51-64}\) and expert recommendations support the use of chemotherapy in these cases.\(^{11,13,39}\)

## Treatment Sequencing in Other NETs

This project also discussed the most appropriate treatments for patients with NETs in other locations (see Table 3).

There was a significant consensus (96\%) on considering \(^{177}\)Lu-DOTATATE for patients with advanced pheochromocytomas/paragangliomas (PPGL) with proven SSTR expression. A systematic literature review including meta-analysis on RLT efficacy and safety in patients with advanced PPGL was retrieved.\(^{65}\) This review, which comprised 12 observational studies, reported an objective response rate of 25\% and disease control rate of 84\%. RLT was associated with the following Grade 3 or 4 undesirable effect rates: neutropenia 3\%, thrombocytopenia 9\%, lymphopenia 11\%, and nephrotoxicity 4\%.\(^{65}\)

Similarly, in progressive advanced nonfunctional PPGL patients, positive metiodobenzylguanidine (MIBG) and SSTR expression, \(^{131}\)I-MIBG (consensus, 92\%) and \(^{177}\)Lu-DOTATATE (consensus, 77\%) were considered the most appropriate treatments. However, in functional tumors with uncontrolled hormonal symptoms, in addition to MIBG (consensus, 92\%) and \(^{177}\)Lu-DOTATATE (consensus, 85\%), SSAs (consensus, 77\%) were considered the most suitable treatments. In phase II RCTs of \(^{131}\)I-MIBG, the objective response rate (RECIST criteria) was around 25\%, while long-term survival reached up to 6 years.\(^{56,67}\) \(^{131}\)I-MIBG-emergent undesirable effects of Grade 3-4 were reported in 16\%-83\% of patients.\(^{56,68}\) As described before, there are promising data concerning \(^{177}\)Lu-DOTATATE in advanced PPGL.\(^{65}\) Concerning SSAs, the evidence in these patients is still scarce.

Advanced PPGL patients with SSTR expression and FDG-PET-CT uptake were analyzed upon disease progression. Among Delphi participants, different levels of disagreement were obtained regarding the most appropriate therapy, including \(^{177}\)Lu-DOTATATE, SSAs, or chemotherapy (cyclophosphamide plus vincristine plus dacarbazine or temozolomide).

Concerning G1-G2 advanced bronchial NET patients with SSTR expression, the following strategy was considered appropriate: first-line treatment with SSAs (unanimity, 100\%), everolimus (consensus, 96\%), and \(^{177}\)Lu-DOTATATE (majority, 65\%); second-line at progression under SSAs, and if FDG-PET-CT uptake, chemotherapy (TEMCAPE) (consensus, 96\%) or everolimus (majority, 73\%). The efficacy and safety of first-line SSA treatment in advanced bronchial NETs have been evaluated in observational studies, showing symptom control.\(^{49}\) Although there were no data confirming tumor growth control in advanced bronchial NET patients, positive experiences were made in tumors of other locations.\(^{53,56}\) A subgroup analysis of RADIANT-4 study involving patients with advanced nonfunctional bronchial NETs, with some of them

| Tumor characteristics | Most appropriate treatment |
|-----------------------|---------------------------|
| Pheochromocytomas/paragangliomas | SSTR expression and MIBG positive |
| Bronchial NETs | G1-G2 |
| | Positive SSTR imaging |
| | Progressing |
| | Nonfunctional |
| | MBG |
| | \(^{177}\)Lu-DOTATATE |
| | Functional with uncontrolled hormonal symptoms |
| | MBG |
| | \(^{177}\)Lu-DOTATATE |
| | SSAs |
| | 1\(^{st}\) line |
| | SSAs |
| | Everolimus |
| | \(^{177}\)Lu-DOTATATE |
| | Positive FDG-PET-TC |
| | Chemotherapy (temozolomide and capecitabine) |
| | Everolimus |

**Table 3.** Treatments for patients with advanced pheochromocytomas/paragangliomas and bronchial neuroendocrine tumors.

Abbreviations: NETs, neuroendocrine tumors; G, grade; SSTR, somatostatin receptor; MIBG, meta-iodobenzylguanidine; FDG-PET-TC, 2-fluoro-2-deoxy-d-glucose-potiron-electron tomography-computed tomography; SSAs, somatostatin analogs.
progressing under SSAs, revealed a significant improvement in PFS with everolimus versus placebo, namely 11 months versus 3.9 months (P < .001), with tumor shrinkage seen in a higher percentage of patients (58% vs 13%), and a trend toward longer OS.71,72 Similarly, a retrospective observational study demonstrated everolimus efficacy in patients with advanced, progressive, and well-differentiated NETs regardless of FDG-PET-TC uptake.73 For 177Lu-DOTATATE, evidence for advanced bronchial NET patients was retrieved from small observational studies and a phase III RCT involving 23 patients. Observed overall response rates ranged from 13% to 30%, PFS from 19 to 28 months, and OS from 32 to 59 months.74-77 Chemotherapy (TEMCAP) has proven effective in small observational studies involving advanced NET patients.78-83 All these considerations very much aligned with clinical guidelines.13,18

Considering G1-G2 advanced bronchial NET patients, the following were considered key factors for selecting 177Lu-DOTATATE: SUV uptake in Gallium-PET (consensus, 93%), progression under everolimus (consensus, 92%), or progression under SSAs (consensus, 92%). As previously mentioned, in the absence of robust data and considering its efficacy and safety profile, 177Lu-DOTATATE would currently be reserved for second- or third-line treatment in advanced bronchial NET patients.15,79

RLT Re-treatment
Concerning RLT re-treatment, the Delphi participants agreed that patients responding to a first RLT course could respond to subsequent RLT courses (consensus, 96%).

The efficacy and safety of RLT re-treatment have been analyzed in small observational studies, in patients with progressing NETs at different sites and stages. There was a great variability in the number of cycles (up to 9 cycles) and cumulative doses administered.80-89 The published median PFS with RLT re-treatment varied from 6 to 22 months. There were also case studies retrieved reporting up to 4 RLT re-treatment courses, with median PFS of 18.9, 12.1, 9.3, and 4.3 months, respectively.87 Median OS varied depending on the study, ranging from 9 to 93.9 months.80-83 Recently, 2 systematic literature reviews and meta-analyses have found (aggregated data) an objective response rate of 17.1%, and disease control rate of 76.9% with RLT re-treatment in advanced NET patients.80,91

As maximum cumulative doses of 177Lu-DOTATATE have yet not been established, a Delphi agreement was attained that RLT re-treatment may be preferred over targeted therapy in pancreatic NET patients with a long-term response (consensus, 77%). In the literature, many patients on RLT re-treatment responded to this therapy for more than 1 year before experiencing progression.90,91 For the panelists, RLT re-treatment is also likely to be an option in well- or moderately differentiated NET patients, especially with a Ki67 of 10%-20% (100% unanimity). Notably, the RLT re-treatment efficacy has been mainly analyzed in well-differentiated NET patients.80,91

For RLT re-treatment, the Delphi members agreed on the following selection criteria: time to progression, previous objective response, tumor burden, location of the primary NET, and subsequent treatment options.

Likewise, an agreement was reached to consider RLT re-treatment if the time to progression was 12 months at least (consensus, 96%). Many published studies have additionally established a PFS >18 months from the first RLT cycle as a criterion indicative for RLT re-treatment.80-88,90,91

Safety issues were evaluated, as well. Disagreement was obtained with a statement suggesting that there was no increase in the incidence of myelodysplastic syndrome or acute leukemia observed with RLT re-treatment, and with another statement declaring no increased risk of nephrotoxicity or hematological toxicity (mainly thrombocytopenia) with RLT re-treatment. In the literature, very few patients experienced Grade 3-4 nephrotoxicity, while the reported rate of myelodysplastic syndrome or acute leukemia was 0%-2.2%.80-91

Neoadjuvant Treatment
Table 4 depicts a summary of the role of neoadjuvant therapy in NET patients.

In locally advanced pancreatic NETs, which are considered nonresectable due to vascular invasion, with Ki-67 ≤10% and SSTR expression, chemotherapy (consensus, 85%) and RLT (majority, 65%) were considered adequate to attain resectability. Chemotherapy was deemed indicated in patients with a possible chance of achieving a response, thereby enabling surgery.83 In pancreatic NETs, there was not a clear Ki-67 cut-off value found for recommending chemotherapy, but generally speaking, a Ki-67 cut-off value between 5% and 20% was considered acceptable.92 In addition, published case studies involving pancreatic NET patients for whom RLT was prescribed reported promising results obtained with neoadjuvant treatment administered for subsequent surgery.92,93

When no response was obtained with chemotherapy in seeking resectability, the preferred options for second-line treatment were SSAs upon progression if resectability was not targeted (consensus, 80%) or RLT to achieve resectability (majority, 66%). According to published reports, RLT may play a role as neoadjuvant therapy in these patients.94

On the contrary, in locally advanced pancreatic NETs, which are considered unresectable due to vascular invasion, exhibiting Ki-67 ≤10%, SSTR expression, and fluorodeoxyglucose (FDG)-PET positivity (SUVm 5-7) as well, chemotherapy would seem adequate to target resectability (consensus, 88%). FDG-PET increased activity may indicate rapid progression of pancreatic NETs, even if these tumors are diagnosed at an early stage or turn out to be well-differentiated. This technique may enable an early identification of undifferentiated clones that affect the patient's prognosis and outcome.95 In more aggressive or poorly differentiated tumors, chemotherapy appears an appropriate option.11,63

Considering pancreatic NETs, with Ki-67 ≤10%, SSTR expression, and resectable “borderline” liver metastases, experts considered the following appropriate: (a) loco-regional therapy (eg, yttrium-90) followed by surgery (unanimity, 100%); (b) RLT followed by surgery if response (consensus, 81%); (c) chemotherapy followed by surgery if response (consensus, 77%). Loco-regional treatments in advanced NETs (including pancreatic NETs) may induce cytotoxic and ischemic damage to metastases, thereby increasing the possibility of surgery.12 Regional control of liver metastases may be achieved (50%-80% 5-year OS in small retrospective series) with loco-regional therapy.11,45,50,96-100 These therapies may be considered as an alternative to systemic therapies if surgery of the primary tumor is envisioned, if the metastatic disease is limited to the liver. Concerning RLT, case series of advanced
Table 4. Neoadyuvant therapies in neuroendocrine tumors.

| Tumor characteristics | Most appropriated treatment |
|-----------------------|-----------------------------|
| Locally advanced pancreatic NET nonresectable due to vascular invasion | Chemotherapy to achieve resectability RLT to achieve resectability SSAs upon progression if resectability is not considered RLT to achieve resectability Chemotherapy to achieve resectability |
| Pancreatic NETs Ki-67 ≤10% SSTR expression | Progression to first-line chemotherapy that sought resectability FDG-PET positive (SUVm 5-7) Resectable ‘borderline’ liver metastases |
| Intestinal NETs Ki-67 ≤10% SSTR expression | Locally advanced, nonresectable due to vascular invasion Resectable ‘borderline’ liver metastases |
| Colorectal NETs Ki-67 ≤10% SSTR expression | Resectable ‘borderline’ liver metastases |
| Bronchial NETs G1-G2 SSTR expression | Large-volume, localized, and probable pneumonectomy |

Abbreviations: NETs, neuroendocrine tumors; G, grade; SSTR, somatostatin receptor; RLT, radioligand therapy; FDG-PET, 2-fluoro-2-deoxy-d-glucose-positron-electron tomography; SSAs, somatostatin analogs; SUV, standardized uptake value.

Discussion

In the current project, we have identified different issues and controversies pertaining to NETs, critically evaluated the available evidence, and provided oncologists with specific information in the form of several statements that all have undergone a Delphi process. We have put a special focus on advanced cases and on the role of RLT.

First, we would like to highlight some general points. For the experts, given the variety of treatment options, heterogeneity of NETs, and individual disease complexities, it appeared strongly recommended that the most appropriate therapeutic strategy should be discussed within a NET-dedicated multidisciplinary team. As regard patient monitoring, oncologists should be aware that a combined approach consisting of clinical symptom evaluation, anatomical imaging, molecular imaging, and biomarker analysis is necessary to properly assess disease progression and treatment response, given that each of these factors presents with several limitations.

Concerning advanced small intestine NETs, and in line with clinical guidelines, the efficacy and safety profile of RLT was considered superior to those of everolimus, and therefore recommended (if available) to be administered prior to the targeted drug in many cases. The proper treatment sequence needs to be further investigated, and it is currently evaluated in phase III RCTs. In this type of NETs with disease progression under SSAs and peritoneal carcinomatosis, RLT was also the preferred option. As regard patient monitoring, oncologists should be aware that a combined approach consisting of clinical symptom evaluation, anatomical imaging, molecular imaging, and biomarker analysis is necessary to properly assess disease progression and treatment response, given that each of these factors presents with several limitations.

Concerning advanced gastrointestinal NETs with bone or liver metastases.
The experts similarly agreed on using SSAs as standard first-line therapy in functioning advanced NETs. In the CLARINET study, lanreotide was associated with significantly prolonged PFS among patients with metastatic enteropancreatic NETs G1-2, with Ki-67 <10%.\textsuperscript{13} When advanced pancreatic NETs were analyzed, for asymptomatic patients with low tumor burden and disease progression under SSAs, everolimus or sunitinib were the preferred second-line treatment options.\textsuperscript{40,64} Given this scenario, achieving an objective response does not appear to be a treatment goal priority. Therefore, RLT and chemotherapy may not be given less preference over novel targeted therapies.\textsuperscript{39,74,101-107} Besides, oral treatment is more comfortable for patients. On the other hand, in case of functional NETs with early progression under SSAs, RLT was recommended.\textsuperscript{41,53,56} Finally, in high tumor burden cases, chemotherapy was the preferred option for the experts, as suggested in clinical guidelines.\textsuperscript{11,18,39,61-64}

Next, different PPGL profiles were discussed. Consensus was obtained on recommending MIBG and \textsuperscript{177}Lu-DOTATATE in metastatic and progressing positive metaiodobenzylguanidine (MIBG) and SST expression PPGL, as well as SSAs in the event of functional, metastatic, and progressing PPGL cases. The evidence in these cases mainly comes from observational experiences,\textsuperscript{63,64} whereas the evidence for SAs is still very scarce.\textsuperscript{108} Considering the effect of SSAs in functional NETs and efficacy of RLT in these patients, SAA may indeed be, at least hypothetically, a therapeutic reality. However, there was no consensus achieved for patients with metastatic and progressing PPGL with uptake on both FDG-PET-CT and SST scintigraphy. The therapeutic strategy for metastatic PPGL primarily aims to control excessive catecholamine secretion and tumor burden, given that no curative treatment options are available. The ESMO-EURACAN clinical guidelines for pheochromocytomas were published in 2020. For patients with metastatic PPGL, these guidelines recommended an individualized management approach in case of disease progression, including RLT, chemotherapy, local therapies, or additional treatments.\textsuperscript{16}

In advanced pulmonary NETs G1-G2 with positive SSTR, the panel considered SSA to be the first-line treatment option.\textsuperscript{66} In disease progression cases under SSA, everolimus (consensus) and \textsuperscript{177}Lu-DOTATATE (majority) were the preferred options for second-line treatment.\textsuperscript{13,76,72,74,77} In a retrospective study, everolimus was found to be a valid therapeutic option for advanced, progressive, well-differentiated NETs, even in patients with positive FDG-PET.\textsuperscript{73} Therefore, as expressed by the experts, everolimus could even be considered in positive FDG-PET cases. In this patient subgroup, chemotherapy (TEMCAP) was also deemed a preferred therapy. Although without any robust evidence, it is likely that the association of FDG-PET with more aggressive tumors and a higher proliferative index influenced this decision.\textsuperscript{109}

Data from observational studies have revealed that RLT retreatment can be a therapeutic choice for patients with progressive NETs.\textsuperscript{80-83} Therefore, there was a high agreement among experts concerning this therapeutic strategy. Moreover, as the maximum cumulative dose of \textsuperscript{177}Lu-DOTATATE has not yet been determined, the experts suggested that RLT retreatment could turn out to be preferred over targeted agents in pancreatic NETs for long responders. In fact, RLT retreatment was associated with similar or slightly longer PFS when indirectly compared with the RADIANT-4 results.\textsuperscript{85} In general, patients who showed reasonable response were those who retreated if the time to progression (TTP) was at least 1 year after completion of the last cycle of initial treatment or presented PFS ≥18 months from the first administration of initial RLT.\textsuperscript{80,88,90,91} Thus, the experts agreed on establishing a TTP of 1 year to consider retreatment. Similarly, retreatment with RLT was considered in well or moderately differentiated NETs with Ki67 proliferation index of 10%-20%, probably because of the impact of the Ki67 on response to RLT.\textsuperscript{91} Nevertheless, promising results have also been reported in patients who were retreated with a TTP <1 year or with Ki67 index >20%.\textsuperscript{80} However, in this section, there might have been some confusion/misunderstanding regarding safety issues with retreatment. The experts showed some concerns about the risk of increased hematological and kidney toxicity. The evidence indicates so far that common undesirable effects appear to be similar to those encountered during initial RLT. This unresolved issue may be due to the lack of well-designed studies that would definitively clarify these safety questions encountered with RLT retreatment.

Finally, the role of neoadjuvant therapies was discussed. In locally advanced NETs, in which surgery of the primary tumor is not considered, experts agreed on considering neoadjuvant therapies to seek resectability, such as chemotherapy and RLT in pancreatic NETs,\textsuperscript{14} or RLT in small intestine NETs.\textsuperscript{42,43} This treatment decision is fundamentally based on treatment response, but on other tumor characteristics, as well, including uptake in PET-FDG in pancreatic NETs, which would indicate chemotherapy as the preferred option.\textsuperscript{31,63,95} In patients with borderline or potentially resectable metastases, and despite the lack of robust evidence,\textsuperscript{11,12,49,50,92,96-102} a consensus was achieved to assess neoadjuvant treatment in selected patients, including loco-regional therapy (for pancreatic and enteric NETs), RLT (pancreatic and small intestine NETs), and even chemotherapy (pancreatic NETs) followed by surgery in case of response. On the other hand, there was consensus to consider surgery in pulmonary NETs, G1-G2 patients, with a probable indication for pneumonectomy, as recommended by clinical practice guidelines.\textsuperscript{53,18}

Conclusions
In summary, there are still many gaps regarding the management of patients with advanced NETs. The aim of this position document was to provide a guide in the decision-making process concerning NETs-affected patients, primarily focusing on those areas that might generate clinical questions or controversies in daily practice. For these cases, the experts’ recommendations through a Delphi process have proven to be a valid and useful tool. We believe that the practical framework provided in this document should be instrumental in helping health professionals better manage NET patients, while using RLT in these patients, as well.

Funding
This project was funded by Advanced Accelerator Applications, a Novartis company.

Conflict of Interest
Paula Jiménez-Fonseca: Bristol, Pfizer, MSD, Mylan, Baxter, IPSEN, Adacap (C/A), HRA Pharma, Leoparma, Rovi, Sanofi (Speaker fees), Ipsen (Travel grants); Enrique Grande: Adacap,
AMGEN, Angelini, Astellas, AstraZeneca, Bayer, Blueprint, Bristol Myers Squibb, Caris Life Sciences, Celgene, Clovis Oncology, Eisai, Eusa Pharma, Genetraer, Guardant Health, HRA-Pharma, IPSEN, ITM-Radiopharma, Janssen, Lexicon, Lilly, Merck KGaA, MSD, Nanosting Technologies, Natera, Novartis, ONCODNA (Biosequence), Palex, Pharmamar, Pierre Fabre, Pfizer, Roche, Sanofi-Genzyme, Servier, Taiho, Thermo Fisher Scientific (C/A), Pfizer, AstraZeneca, Astellas, Lexicon Pharmaceuticals (RF); Rocío García-Carbonero: AAA, Advanz Pharma, Amgen, Bayer, BMS, HMP, Ipsen, Merck, Midatech Pharma, MSD, Novartis, PharmMar, Pfizer, Pierre Fabre, Roche, Servier, Sanofi (C/A), Pfizer, BMS, MSD (RF). The other authors indicated no financial relationships.

(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board.

Author Contributions

Conception/design: J.C. Collection and/or assembly of data: J.C., E.G., R.G.-C., M.S., M.T., O.G., P.J.-E., A.C.-B., and V.P. Data analysis and interpretation: J.C., E.G., R.G.-C., M.S., M.T., O.G., P.J.-E., A.C.-B., and V.P. Manuscript writing: J.C. Final approval of manuscript: All authors.

Data Availability

The data underlying this article will be shared at reasonable request to the corresponding author.

Supplementary Material

Supplementary material is available at The Oncologist online.

References

1. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):1-18, vii.
2. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with Neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335-1342.
3. Lee MR, Harris C, Baeg KJ, Aronson A, Wisnivesky JP, Kim MK. Incidence trends of gastroenteropancreatic neuroendocrine tumors in the United States. Clin Gastroenterol Hepatol. 2019;17(11):2212-2217.e1.
4. NiederleMB, HackML, KasererKN, NiederleB. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: a analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17(4):909-918.
5. Frilling A, Modlin IM, Kidd M, et al.; Working Group on Neuroendocrine Liver Metastases. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8-21.
6. Pape UF, Berndt U, Müller-Nordhorn J, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008;15(4):1083-1097.
7. Ambrosini V, Kunikowska J, Baudin E, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021;146:56-73.
8. Arakelyan J, Zohrabyan D, Philip PA. Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): opportunities for personalized therapies. Cancer. 2021;127(3):345-353.
9. Sato Y, Hashimoto S, Mizuno K, Takeuchi M, Terai S. Management of gastric and duodenal neuroendocrine tumors. World J Gastroenterol. 2016;22(30):6817-6828.
10. Koffas A, Toumpanakis C. Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors. Expert Opin Drug Saf. 2021;20(3):321-334.
11. Pavel M, O’Toole D, Costa F, et al.; Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016;103(2):172-185.
12. Blanco Carrera C, Crespo Vallejo E, Gamo Gallego M, et al. QUIMIOEMBOLIZACIÓN ARTERIAL SELECTIVA EN TUMORES NEUROENDOCRINOS (TNE) GASTROENTEROPANCREÁTICOS CON RECÍDIVA LOCOREGIONAL O METÁSTASIS HEPÁTICAS. EXPERIENCIA PRELIMINAR. Endocrinol Nutr. 2016;63(Espec Cong 2):224.
13. Caplin ME, Baudin E, Ferolla P, et al.; ENETS consensus conference participants. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604-1620.
14. Delle Fave G, O’Toole D, Sundin A, et al.; Vienna Consensus Conference participants. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):119-124.
15. Falconi M, Eriksson B, Kaltas G, et al.; Vienna Consensus Conference participants. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153-171.
16. Fassnacht M, Assie G, Baudin E, et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Adrenocortical carcinomas and malignant pheochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1476-1490.
17. García-Carbonero R, Sorbye H, Baudin E, et al.; Vienna Consensus Conference participants. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103(2):186-194.
18. González-Flores E, Serrano R, Sevilla I, et al. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018). Clin Transl Oncol. 2019;21(1):55-63.
19. Kianmanesh R, Ruszniewski P, Rindi G, et al.; Palma de Mallorca Consensus Conference Participants. ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors. Neuroendocrinology. 2010;91(4):333-340.
20. Kos-Kudla B, O’Toole D, Falconi M, et al.; Palma de Mallorca Consensus Conference Participants. ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology. 2010;91(4):341-350.
21. Ramirez JK, De Herder WW, Delle Fave G, et al.; Vienna Consensus Conference participants. ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):139-143.
22. Strosberg JR, Halfdanarson TR, Bellizzi AM, et al. The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Panreats. 2017;46(6):707-714.
23. Knigge U, Capdevila J, Bartsch DK, et al.; Antibes Consensus Conference Participants; Antibes Consensus Conference participants. ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms: follow-up and documentation. Neuroendocrinology. 2017;105(3):310-319.
24. Merino-Casabiel X, Aller J, Arbizu J, et al. Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors. Clin Transl Oncol. 2018;20(12):1522-1528.
25. Sundin A, Arnold R, Baudin E, et al.; Antibes Consensus Conference participants. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology. 2017;105(3):212-244.

26. de Mestier L, Dromain C, d’Assignies G, et al. Evaluating diagnostic neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocr Relat Cancer. 2014;21(3):R105-R120.

27. Broder MS, Benero D, Strosberg JR, Neary MP, Cheerepanov D. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. J Gastroenterol. 2015;51(6):1945-1955.

28. Yadegarfar G, Friend L, Jones L, et al.; EORTC Quality of Life Group. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life in patients with gastrointestinal neuroendocrine tumours. Br J Cancer. 2013;108(2):301-310.

29. Braga F, Ferraro S, Mozza R, Dolci A, Panteghini M. Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase. Clin Biochem. 2013;46(1-2):148-151.

30. Vezzosi D, Walter T, Laplanche A, et al. Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study. Int J Biol Markers. 2011;26(2):94-101.

31. Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2012;19(1):111-34.

32. Van Cutsem E, Dicato M, Geva R, et al. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol. 2011;22(Suppl 5):v1-9.

33. Yao JC, Pavel M, Phan AT, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011;96(12):3741-3749.

34. Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol. 2007;25(15):1967-1973.

35. Haug AR, Auerhammer CJ, Wängler B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51(9):1349-1356.

36. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25(13):1753-1759.

37. Favier S, Ronot M, Dreyer C, et al. Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. Target Oncol. 2012;7(2):127-133.

38. Dreyer C, Hentic O, Zappa M, et al. 1163P—response evaluation using Recist and Choi criteria in patients with well-differentiated pancreatic Neuroendocrine Tumors (PNET) treated with Sunitinib or Everolimus. Ann Oncol. 2012;23(Supplement 9):ix379.

39. Pavel M, Öberg K, Falconi M, et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844-860.

40. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501-513.

41. Pavel ME, Hainsworth JD, Baudin E, et al.; RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005-2012.

42. Strosberg J, El-Haddad G, Wolin E, et al.; NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125-135.

43. Strosberg J, Wolin E, Chasen B, et al.; NETTER-1 Study Group. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018;36(25):2578-2584.

44. Castellano D, Bajetta E, Pannerselvam A, et al.; RADIANT-2 Study Group. Everolimus plus octreotide-long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study. Oncologist. 2013;18(1):46-53.

45. Singh S, Carnaghi C, Buzzoni R, et al.; RAD001 in Advanced Neuroendocrine Tumors, Fourth Trial (RADIANT-4) Study Group. Everolimus in neuroendocrine tumors of the gastrointestinal tract and unknown primary. Neuroendocrinology. 2018;106(3):211-220.

46. Kwakkelboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23(12):2754-2762.

47. Chan JA, Kulke MH. Emerging therapies for the treatment of patients with advanced neuroendocrine tumors. Expert Opin Emerg Drugs. 2007;12(2):253-270.

48. Strosberg J, Kunz PL, Hendifar A, et al.; NETTER-1 study group. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020;47(10):2372-2382.

49. Akyildiz HY, Mitchell J, Milas M, Siperstein A, Berber E. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery. 2010;148(6):1288-93; discussion 1293.

50. Yang TX, Chua TC, Morris DL. Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases—a systematic review. Surg Oncol. 2012;21(4):299-308.

51. Medaer A, Verslype C, Van Cutsem E, et al. Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of 177Lu-DOTATATE PRRT. Acta Oncol. 2020;59(6):644-651.

52. Saber A, Ezziddin K, Pape UF, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2013;54(11):1857-1861.

53. Caplin ME, Pavel M, Řídková JB, et al.; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224-233.

54. Yao JC, Shah MH, Ito T, et al.; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-523.

55. Satapathy S, Mittal BR. 177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Nucl Med Commun. 2019;40(12):1195-1203.

56. Capdevila J, Hernandez J, Perez-Hoyos S, Roman-Gonzalez A, Grande E. Meta-analysis of randomized clinical trials comparing active treatment with placebo in metastatic neuroendocrine tumors. Oncologist. 2019;24(12):e1315-e1320.

57. Bernard V, Lombard-Bolas C, Taquet MC, et al.; French Group of Endocrine Tumors. Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. Eur J Endocrinol. 2013;168(5):665-674.

58. Fiebrich HB, Siemertink EJ, Brouwers AH, et al. Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. Oncologist. 2011;16(6):783-787.

59. Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med. 2009;360(2):195-197.

60. van Schaik E, van Vliet EI, Feelders RA, et al. Improved control of severe hypoglycaemia in patients with malignant insulinomas by peptide receptor radionuclide therapy. J Clin Endocrinol Metab. 2011;96(11):3381-3389.
61. Clewemar Antonomidouakis P, Sundin A, Wassberg C, Granberg D, Skogseid B, Eriksson B. Streptozocin and 5-fluorouracil for the treatment of pancreatic neuroendocrine tumors: efficacy, prognostic factors and toxicity. Neuroendocrinology. 2016;103(3-4):345-353.

62. Kunz PL, Catalano PJ, Nimeiri H, et al. A randomized study of temozolomide or temozolomide and capcitabine in patients with advanced pancreatic neuroendocrine tumors: a trial of the ECOG-ACRIN Cancer Research Group (E2211). Journal of Clinical Oncology. 2018;36(15):4004.

63. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22(23):4762-4771.

64. Fine RL, Gulati AP, Kranitz BA, et al. Capcitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol. 2013;71(3):663-670.

65. Satapathy S, Mittal BR, Bhanzali A. ‘Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis’. Clin Endocrinol (Oxf). 2019;91(6):718-727.

66. Gonias S, Goldsby R, Matthey KK, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27(23):4162-4169.

67. Pryma DA, Chin BB, Noto RB, et al. Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med. 2019;60(5):626-630.

68. Pacak K, Eisenhofer G, Ahlman H, et al.; International Symposium on Pheochromocytoma. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab. 2007;3(2):92-102.

69. Filosso PL, Ruffini E, Oliaro A, Papalia E, Donati G, Rena O. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg. 2002;21(5):913-917.

70. Rinke A, Muller HH, Schade-Brittinger C, et al.; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656-4663.

71. Yao JC, Fazio N, Singh S, et al.; RAD001 in Advanced Neuroendocrine Tumors, Fourth Trial (RADIAN-T4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumors of the lung or gastrointestinal tract (RADIAN-T4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968-977.

72. Fazio N, Buzzoni R, Delle Fave G, et al. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIAN-4 lung subgroup analysis. Cancer Sci. 2018;109(1):174-181.

73. Rinzivillo M, Prosperi D, Mazzuca F, et al. 1185P [18F]FDG-PET/CT and long-term response to everolimus in advanced neuroendocrine neoplasia. Ann Oncol. 2020;31:S782.

74. Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617-4624.

75. Baum RP, Kulkarni HR, Singh A, et al. Results and adverse events of personalized peptide receptor radionuclide therapy with [18]Yttrium and [177]Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget. 2018;9(24):16932-16950.

76. Parghane RV, Talole S, Prabhak K, Basu S. Clinical response profile of metastatic/advanced pulmonary neuroendocrine tumors to peptide receptor radionuclide therapy with [177]Lu-DOTATATE. Clin Nucl Med. 2017;42(6):428-435.

77. Sabet A, Haug AR, Eiden C, et al. Efficacy of peptide receptor radionuclide therapy with [177]Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis. Am J Nucl Med Mol Imaging. 2017;7(2):74-83.

78. Spada F, Antonuzzo L, Marconcini R, et al. Chemotherapy with capcitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NENs): an Italian multicenter retrospective analysis. J Clin Oncol. 2015;33(15_suppl):e15174-e.

79. Hope TA, Bodie L, Chan JA, et al. NANETS/SNMMI consensus statement on patient selection and appropriate use of [177]Lu-DOTATATE peptide receptor radionuclide therapy. J Nucl Med. 2020;61(2):222-227.

80. van der Zwan WA, Brabander T, Kam BLR, et al. Salvage peptide receptor radionuclide therapy with [177]Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2019;46(3):704-717.

81. Vaughn E, Machta J, Walker M, Toumanakis C, Caplin M, Navalkissoor S. Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response. Br J Radiol. 2018;91(1091):20180041.

82. Makis W, McCann K, Riauka TA, McEwan AJ. Ectopic corticotropin-producing neuroendocrine tumor of the pancreas treated with [177]Lu-DOTATE induction and maintenance peptide receptor radionuclide therapy. Clin Nucl Med. 2016;41(1):50-52.

83. Rudisile S, Gosewisch A, Wenter V, et al. Salvage PRRT with [177]Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET) somatostatin receptor expression, toxicity, efficacy, and survival. BMC Cancer. 2019;19(1):788.

84. Sabet A, Haderud T, Pape UF, et al. Outcome and toxicity of salvage therapy with [177]Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41(2):205-210.

85. Severi S, Sansovini M, Ianniello A, et al. Feasibility and utility of re-treatment with [177]Lu-DOTATE in GEP-NENs relapsed after treatment with [90]Y-DOTATOC. Eur J Nucl Med Mol Imaging. 2015;42(13):1955-1963.

86. van Essen M, Krenning EP, Kam BL, de Herder WW, Feelders RA, Kwakkeboom DJ. Salvage therapy with [177]Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2010;51(3):383-390.

87. Yordanova A, Mayer K, Brossart P, et al. Safety of multiple repeated cycles of [177]Lu-octreotate in patients with recurrent neuroendocrine tumour. Eur J Nucl Med Mol Imaging. 2017;44(7):1207-1214.

88. Yordanova A, Mayer K, Essler M, Ahmadzadehfar H. Successful repeated peptide receptor radionuclide therapies in renal neuroendocrine tumor with osseous metastasis. Clin Nucl Med. 2016;41(12):977-979.

89. Severi S, Grassi I, Nicolini S, Sansovini M, Bongiovanni A, Paganeli G. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. Onco Targets Ther. 2017;10:551-557.

90. Strosberg J, Leeuwenkamp O, Siddiqui MK. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumours: a systematic review and meta-analysis. Cancer Treat Rev. 2021;93:102141.

91. Kim YI. Salvage peptide receptor radionuclide therapy in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis. Nucl Med Commun. 2021;42(4):451-458.

92. van Vliet EI, van Eijck CH, de Krijger RR, et al. Neoadjuvant peptide receptor radionuclide therapy for nonfunctioning pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med. 2015;56(11):1647-1653.

93. Kaasaunerer D, Prasad V, Daffner W, et al. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol. 2009;15(46):5867-5870.

94. Barber TW, Hofman MS, Thomson BN, Hicks RJ. The potential for induction peptide receptor chemoradi nuclide therapy to render...
inoperable pancreatic and duodenal neuroendocrine tumours resectable. Eur J Surg Oncol. 2012;38(1):64-71.

95. Calabrò D, Argalia G, Ambrosini V. Role of PET/CT and therapy management of pancreatic Neuroendocrine Tumors. Diagnostics (Basel). 2020;10(12):1059.

96. de Baere T, Deschamps F, Tselikas L, et al. GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETS. Eur J Endocrinol. 2015;172(4):R151-R166.

97. Fiore F, Del Prete M, Franco R, et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 2014;47(1):177-182.

98. Engelman ES, Leon-Ferre R, Naraev BG, et al. Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution. Pancreas. 2014;43(2):219-225.

99. Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski P; NET-Liver-Metastases Consensus Conference. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford). 2015;17(1):29-37.

100. Benson AB 3rd, Geschwind JF, Mulcahy MF, et al. Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer. 2013;49(15):3122-3130.

101. Ezziddin S, Lauschke H, Schaefers M, et al. Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors. Clin Nucl Med. 2012;37(1):102-104.

102. da Silva TN, van Velthuysen MLF, van Eijck CHJ, et al. Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour. Endocrinol Diabetes Metab Case Rep. 2018;2018(1):18-0015.

103. Maire F, Lombard-Bohas C, O’Toole D, et al. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study. Neuroendocrinology. 2012;96(4):294-300.

104. Strosberg JR, Al-Toubah T, Pellé E, et al. Risk of bowel obstruction in patients with mesenteric or peritoneal disease receiving peptide receptor radionuclide therapy. J Nucl Med. 2021;62(1):69-72.

105. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980;303(21):1189-1194.

106. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326(8):519-523.

107. Kunz PL, Catalano PJ, Nimeiri H, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: a trial of the ECOG-ACRIN Cancer Research Group (E2211). J Clin Oncol. 2018;36(15_suppl):4004.

108. Rossini A, Perticone F, Frosio L, Schiavo Lena M, Lanzi R. Somatostatin analog challenge test in the pre-surgical management of ACTH-secreting pheochromocytoma. Endocrinol Diabetes Metab Case Rep. 2019;2019:19-0123.

109. Bucau M, Laurent-Bellue A, Poté N, et al. 18F-FDG uptake in well-differentiated neuroendocrine tumors correlates with both Ki-67 and VHL pathway inactivation. Neuroendocrinology. 2018;106(3):274-282.